Haemonetics Corporation (HAE) announced receipt of the FDA 510(k) clearance for the TEG 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge. This new cartridge expands Haemonetics' TEG 6s viscoelastic testing capabilities to include fully heparinized patients undergoing adult cardiovascular surgeries/procedures and liver transplants in both laboratory and point-of-care settings.The recent development will fortify Haemonetics’ portfolio of hemostasis diagnostic systems.More on TEG 6s Cartridge ...

BOSTON, April 4, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the TEG® 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge. This new cartridge extends Haemonetics' TEG 6s viscoelastic testing capabilities to serve fully heparinized patients in adult cardio ...

Haemonetics Corporation (NYSE:HAE) Q3 2024 Earnings Conference Call February 8, 2024 8:00 AM ET Company Participants Olga Guyette – Senior Director-Investor Relations and Treasury Chris Simon – Chief Executive Officer James D'Arecca – Chief Financial Officer Conference Call Participants Andrew Cooper – Raymond James Mike Matson – Needham & Company David Turkaly – JMP securities Operator Good day and thank you for standing by. Welcome to Haemonetics Corporation Third Quarter Fiscal 2024 Earnings Conference ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 30, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☐ 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 04-2882273 (State or other jurisdiction of incorporation or organizat ...

Haemonetics Corporation (NYSE:HAE) Q2 2024 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Olga Guyette – Senior Director, Investor Relations and Treasury Chris Simon – Chief Executive Officer Stewart Strong – President of our Global Hospital business James D'Arecca – Chief Financial Officer Conference Call Participants Anthony Petrone – Mizuho Group Lee Jagoda – CJS Securities Andrew Cooper – Raymond James Mike Matson – Needham & Company Michael Petusky – Barrington Research Opera ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☐ 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 04-2882273 (State or other jurisdiction of incorporation or organiza ...

Haemonetics Corporation (NYSE:HAE) Q1 2024 Earnings Conference Call August 8, 2023 8:00 AM ET Company Participants Olga Guyette - Senior Director-Investor Relations & Treasury Christopher Simon - President and Chief Executive Officer James D'Arecca - Executive Vice President and Chief Financial Officer Conference Call Participants Anthony Petrone - Mizuho Americas Mike Matson - Needham & Company Andrew Cooper - Raymond James Joanne Wuensch - Citi Michael Petusky - Barrington Research Larry Solow - CJS Secur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) Massachusetts 04-2882273 (State or other jurisdiction of incorporation or organization) 125 Summer Street For the quarterly period ended: July 1, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☐ 1934 Commission File Number: 001-14041 HAEMON ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 1, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 04-2882273 (State or other jurisdiction of incorpora ...

Haemonetics Corporation (NYSE:HAE) Q4 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants David Trenk - Manager, Investor Relations Christopher Simon - Chief Executive Officer James D'Arecca - Executive Vice President and Chief Financial Officer Conference Call Participants Anthony Petrone - Mizuho Larry Solow - CJS Securities David Turkaly - JMP Securities Mike Matson - Needham & Company Drew Ranieri - Morgan Stanley Michael Petusky - Barrington Research Operator Good day and thank y ...